reintroducing the IV antifungal Cancidas

July 2002

Merck-Frosst is reintroducing the IV antifungal Cancidas.

Cancidas (caspofungin acetate) was originally marketed last fall...but wasn't widely promoted due to supply problems.

The shortage got so bad that by April the drug was no longer available to new patients. Now the shortage is over.

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter Canada includes:

12 issues every year, with brief articles about new meds and hot topics
120+ CE courses, including the popular CE-in-the-Letter
Helpful, in-depth Technician Tutorials
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

how to treat persistent pain in the elderly
Cholesterol statins might cause peripheral neuropathy
Ophthalmology new prostaglandin eyedrop for glaucoma called Lumigan (bimatoprost)
Women's Health Should women stop taking oral contraceptives before surgery?
Women's Health Zoloft (sertraline) or Prozac (fluoxetine) for premenstrual dysphoric disorder (PMDD)
Kineret (anakinra), a new biotech drug for rheumatoid arthritis
Infectious Diseases Summer travellers are asking about international precautions
Infectious Diseases reintroducing the IV antifungal Cancidas
Infectious Diseases Vfend (voriconazole), a new antifungal
Diabetes when it's appropriate to use "alternate site testing" for measuring blood glucose
angiotensin receptor blockers (ARBs) might help prevent headaches
hyponatremia in patients taking SSRIs (fluoxetine, etc) or venlafaxine (Effexor)
Hematology & Oncology Celebrex (celecoxib) is now approved for a hereditary form of colorectal cancer
Natural Medicines Nexrutine, an herbal ingredient being called a "natural COX-2 inhibitor."
Natural Medicines astaxanthin (as-ta-ZAN-thin), an antioxidant that's popping up in many products
Men's Health men getting BOTH Proscar and an alpha-blocker for benign prostatic hyperplasia